| Primary |
| Chronic Lymphocytic Leukaemia |
34.8% |
| Diffuse Large B-cell Lymphoma Recurrent |
22.2% |
| Lymphoma |
6.9% |
| Prophylaxis |
5.2% |
| Diffuse Large B-cell Lymphoma |
4.3% |
| B-cell Lymphoma |
3.9% |
| Rheumatoid Arthritis |
3.3% |
| Richter's Syndrome |
3.2% |
| Non-hodgkin's Lymphoma |
2.9% |
| Hypertension |
2.5% |
| Mantle Cell Lymphoma |
2.2% |
| Premedication |
1.5% |
| Infection Prophylaxis |
1.3% |
| Chronic Lymphocytic Leukaemia Refractory |
1.2% |
| Nausea |
1.1% |
| Antiviral Prophylaxis |
0.8% |
| Diabetes Mellitus |
0.7% |
| Hodgkin's Disease |
0.7% |
| Antifungal Prophylaxis |
0.6% |
| Diffuse Large B-cell Lymphoma Refractory |
0.6% |
|
| Febrile Neutropenia |
33.2% |
| Pneumonia |
8.9% |
| Pyrexia |
6.6% |
| Neutropenic Sepsis |
6.1% |
| Thrombocytopenia |
4.7% |
| Cytomegalovirus Infection |
4.5% |
| Renal Failure Acute |
4.5% |
| Tumour Lysis Syndrome |
3.9% |
| Vomiting |
3.4% |
| Renal Failure |
3.2% |
| Sepsis |
3.2% |
| Neutropenia |
2.9% |
| Anaphylactic Reaction |
2.4% |
| Nausea |
2.1% |
| Blood Creatinine Increased |
1.8% |
| Dyspnoea |
1.8% |
| Progressive Multifocal Leukoencephalopathy |
1.8% |
| Respiratory Failure |
1.8% |
| Death |
1.6% |
| Infection |
1.6% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
37.7% |
| Product Used For Unknown Indication |
17.4% |
| B-cell Lymphoma |
8.0% |
| Lymphoma |
5.6% |
| Prophylaxis |
5.4% |
| Antifungal Prophylaxis |
4.0% |
| Antiviral Prophylaxis |
3.7% |
| Non-hodgkin's Lymphoma |
3.4% |
| Mantle Cell Lymphoma |
2.9% |
| Hypertension |
1.7% |
| Diffuse Large B-cell Lymphoma Refractory |
1.6% |
| Opsoclonus Myoclonus |
1.6% |
| Vitamin Supplementation |
1.2% |
| Chronic Lymphocytic Leukaemia Recurrent |
1.1% |
| Supplementation Therapy |
1.1% |
| Rheumatoid Arthritis |
1.0% |
| Diffuse Large B-cell Lymphoma Recurrent |
0.8% |
| Herpes Zoster |
0.8% |
| Infusion Related Reaction |
0.6% |
| Premedication |
0.6% |
|
| Pneumonia |
12.1% |
| Neutropenia |
8.9% |
| Febrile Neutropenia |
7.3% |
| Sepsis |
6.5% |
| Haemolysis |
5.6% |
| Neurotoxicity |
5.6% |
| Autoimmune Haemolytic Anaemia |
4.8% |
| Infection |
4.8% |
| Musculoskeletal Disorder |
4.8% |
| Tremor |
4.8% |
| Cytomegalovirus Infection |
4.0% |
| Neutropenic Sepsis |
4.0% |
| Tumour Lysis Syndrome |
4.0% |
| Atrial Fibrillation |
3.2% |
| Cough |
3.2% |
| Fatigue |
3.2% |
| Respiratory Failure |
3.2% |
| Richter's Syndrome |
3.2% |
| Vertigo Labyrinthine |
3.2% |
| Wrist Fracture |
3.2% |
|
| Concomitant |
| Chronic Lymphocytic Leukaemia |
42.0% |
| Product Used For Unknown Indication |
32.0% |
| B-cell Small Lymphocytic Lymphoma |
4.0% |
| Chronic Hepatitis |
4.0% |
| Gout |
4.0% |
| Nausea |
4.0% |
| Pain |
4.0% |
| Vomiting |
4.0% |
| B-cell Lymphoma |
2.0% |
|
| Death |
15.4% |
| Dyspnoea |
15.4% |
| Febrile Neutropenia |
15.4% |
| Neutropenia |
15.4% |
| Electrocardiogram St Segment Depression |
7.7% |
| Haemolytic Anaemia |
7.7% |
| Neutropenic Sepsis |
7.7% |
| Tremor |
7.7% |
| Vomiting |
7.7% |
|
